Furthermore, we would suggest incorporating PAX8 in the panel, which, although non-specific for the renal origin (being positive in endometrial, ovarian and thyroid cancers), has been proven useful in primary and metastatic RCCs. This evidence concerns the gene PAX8 and thyroid cancer.